BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32891738)

  • 1. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial.
    Kimura SI; Kanda Y; Iino M; Fukuda T; Sakaida E; Oyake T; Yamaguchi H; Fujiwara SI; Jo Y; Okamoto A; Fujita H; Takamatsu Y; Saburi Y; Matsumura I; Yamanouchi J; Shiratori S; Gotoh M; Nakamura S; Tamura K;
    Int J Infect Dis; 2020 Nov; 100():292-297. PubMed ID: 32891738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
    Kanda Y; Kimura SI; Iino M; Fukuda T; Sakaida E; Oyake T; Yamaguchi H; Fujiwara SI; Jo Y; Okamoto A; Fujita H; Takamatsu Y; Saburi Y; Matsumura I; Yamanouchi J; Shiratori S; Gotoh M; Nakamura S; Tamura K;
    J Clin Oncol; 2020 Mar; 38(8):815-822. PubMed ID: 31977270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
    Jeong SH; Kim DY; Jang JH; Mun YC; Choi CW; Kim SH; Kim JS; Park JS
    Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
    Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
    Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study.
    Mizuno H; Sawa M; Yanada M; Shirahata M; Watanabe M; Kato T; Nagai H; Ozawa Y; Morishita T; Tsuzuki M; Goto E; Tsujimura A; Suzuki R; Atsuta Y; Emi N; Naoe T
    Int J Hematol; 2013 Aug; 98(2):231-6. PubMed ID: 23857638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.
    Yanada M; Kiyoi H; Murata M; Suzuki M; Iwai M; Yokozawa T; Baba H; Emi N; Naoe T
    Intern Med; 2006; 45(5):259-64. PubMed ID: 16595990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.
    Racil Z; Toskova M; Kocmanova I; Buresova L; Kouba M; Drgona L; Masarova L; Guman T; Tothova E; Gabzdilova J; Forsterova K; Haber J; Ziakova B; Bojtarova E; Rolencova M; Timilsina S; Cetkovsky P; Mayer J
    Leuk Lymphoma; 2013 May; 54(5):1042-7. PubMed ID: 23088794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases.
    Park JS; Kim DH; Choi CW; Jeong SH; Choi JH; Kim K; Kim SJ; Jung CW; Yang DH; Jang JH
    Acta Haematol; 2010; 124(2):92-7. PubMed ID: 20664196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC).
    López-Sánchez C; Valcárcel D; Gómez V; López-Jiménez J; Serrano D; Rubio V; Solano C; Vázquez L; Ruiz I;
    Rev Esp Quimioter; 2020 Apr; 33(2):110-115. PubMed ID: 32056418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.
    Goto N; Hara T; Tsurumi H; Ogawa K; Kitagawa J; Kanemura N; Kasahara S; Yamada T; Shimizu M; Nakamura M; Matsuura K; Moriwaki H
    Am J Hematol; 2010 Nov; 85(11):872-6. PubMed ID: 20882524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.
    Tamura K; Urabe A; Yoshida M; Kanamaru A; Kodera Y; Okamoto S; Maesaki S; Masaoka T
    Leuk Lymphoma; 2009 Jan; 50(1):92-100. PubMed ID: 19172498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of micafungin in unrelated cord blood transplant recipients.
    Yasu T; Konuma T; Oiwa-Monna M; Mizusawa M; Isobe M; Kato S; Takahashi S; Tojo A
    Ann Hematol; 2019 Nov; 98(11):2593-2600. PubMed ID: 31494737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
    Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
    Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis.
    Rothe A; Claßen A; Carney J; Hallek M; Mellinghoff SC; Scheid C; Holtick U; von Bergwelt-Baildon M
    Eur J Haematol; 2020 Apr; 104(4):291-298. PubMed ID: 31856310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies.
    Toubai T; Tanaka J; Ota S; Shigematsu A; Shono Y; Ibata M; Hashino S; Kondo T; Kakinoki Y; Masauzi N; Kasai M; Iwasaki H; Kurosawa M; Asaka M; Imamura M
    Intern Med; 2007; 46(1):3-9. PubMed ID: 17202726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
    Huang X; Chen H; Han M; Zou P; Wu D; Lai Y; Huang H; Chen X; Liu T; Zhu H; Wang J; Hu J
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1509-16. PubMed ID: 22469884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.